Vaxart, Inc.
VXRTVaxart, Inc. is an American biotechnology company focused on the discovery, development, and commercialization of oral recombinant vaccines administered using temperature-stable tablets that can be stored and shipped without refrigeration, eliminating the need for needle injection. Its development programs for oral vaccine delivery (Vector-Adjuvant-Antigen Standardized Technology known as VAAST) include prophylactic, enteric-coated tablet vaccines for inhibiting norovirus, seasonal influenza, respiratory syncytial virus, and human papillomavirus. It was founded in 2004 by Sean Tucker. Originally incorporated as West Coast Biologicals, Inc. in California in 2004, the company later changed its name to Vaxart, Inc. in July 2007, after reincorporating in Delaware. A significant development in the company's history was the reverse merger with Aviragen Therapeutics, Inc. on February 13, 2018, which led to Vaxart becoming a wholly owned subsidiary of Aviragen. Post-merger, the company continued as Vaxart, Inc.
Drugs in Pipeline
6
Phase 3 Programs
0
Upcoming Catalysts
1
Next Catalyst
May 2027
Market Overview
Stock performance and key metrics
1 upcoming, 0 past
How VXRT's past catalysts played out
Open label Bivalent GII.4/GI.1 high dose vaccine 2×10 to the power 11 IU/dose
Norovirus Infections
VXA-CoV2-3.1
SARS-CoV2
VXA-A1.1
Influenza
AP611074 5% gel
Condyloma
VXA-G1.1-NN
Norovirus Infections
Norovirus GI.1 Norwalk Virus Inoculum
Norovirus Infections
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Open label Bivalent GII.4/GI.1 high dose vaccine 2×10 to the power 11 IU/dose | Phase 2 | Norovirus Infections | - | - |
VXA-CoV2-3.1 | Phase 2 | SARS-CoV2 | - | - |
VXA-A1.1 | Phase 2 | Influenza | - | - |
AP611074 5% gel | Phase 2 | Condyloma | - | - |
VXA-G1.1-NN | Phase 2 | Norovirus Infections | - | - |
Norovirus GI.1 Norwalk Virus Inoculum | Phase 2 | Norovirus Infections | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Vaxart, Inc.'s drug pipeline?→
CatalystAlert tracks 6 drug candidates in Vaxart, Inc.'s (VXRT) pipeline across Phase 2. Its lead program is Open label Bivalent GII.4/GI.1 high dose vaccine 2×10 to the power 11 IU/dose (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Vaxart, Inc.'s next FDA catalyst?→
Vaxart, Inc.'s (VXRT) next tracked catalyst is a Phase 2 expected May 15, 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track VXRT biotech catalysts?→
Add VXRT to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Vaxart, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.